# A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

> **NCT04237116** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Plaque Psoriasis
- Non-alcoholic Fatty Liver Disease

## Interventions

- **BIOLOGICAL:** Investigational Arm - secukinumab
- **BIOLOGICAL:** Control Arm - placebo

## Key facts

- **NCT ID:** NCT04237116
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-19
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-07-23
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237116, "A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04237116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*